EUVIMEDEUVIMED entdecken
Open Access

Hybrid Non‐Informative and Informative Prior Model‐Assisted Designs for Mid‐Trial Dose Insertion

Masahiro Kojima iD, Kana Yamada, Hisato Sunami, Kentaro Takeda, Keisuke Hanada

Statistics in Medicine · 2026

DOI: 10.1002/sim.70733 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Statistics in Medicine, 2026. Verfasst von Masahiro Kojima und 4 weiteren Autor:innen. Beteiligte Einrichtung: Chuo University, Tokyo, Japan. Hauptthemen laut MEDLINE: Maximum Tolerated Dose, Models, Statistical, Clinical Trials, Phase I as Topic, Research Design. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: JSPS KAKENHI.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In oncology phase I trials, model‐assisted designs have been increasingly adopted because they enable adaptive yet operationally simple dose adjustment based on accumulating safety data, leading to a paradigm shift in dose‐escalation methodology. In practice, a single mid‐trial dose insertion may be considered to examine safer doses and/or to collect more informative efficacy data. In this study, we investigate methods to improve dose assignment and the selection of the maximum tolerated dose (MTD) or the optimal biological dose (OBD) when a new dose level is added during an ongoing trial under a model‐assisted framework, by assigning informative prior information to the inserted dose. We propose a hybrid design that uses a non‐informative model‐assisted design at trial initiation and, upon dose insertion, applies an informative‐prior extension only to the newly added dose. In addition, to address potential skeleton misspecification, we propose two adaptive extensions: (i) an online‐weighting approach that updates the skeleton over time, and (ii) a Bayesian‐mixture approach that robustly combines multiple candidate skeletons. We evaluate the proposed methods through simulation studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Maximum Tolerated DoseModels, StatisticalClinical Trials, Phase I as TopicResearch DesignAntineoplastic AgentsHumansBayes TheoremDose-Response Relationship, DrugComputer Simulation

Stichwörter der Autor:innen

Bayesian optimal interval designinformative designnon‐informative designoptimal biological dose

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Chuo University, Tokyo, Japan.
  • The Institute of Statistical Mathematics, Tokyo, Japan.
  • Institute of Science Tokyo, Tokyo, Japan.
  • The University of Osaka, Osaka, Japan.
  • Astellas Pharma Global Development Inc., Tokyo, Japan.
  • Wakayama Medical University, Wakayama, Japan.

ORCID-Profile: Masahiro Kojima

Förderung

  • JSPS KAKENHI

Zitieren

APA

Kojima, M., Yamada, K., Sunami, H., Takeda, K., & Hanada, K. (2026). Hybrid Non‐Informative and Informative Prior Model‐Assisted Designs for Mid‐Trial Dose Insertion. Statistics in Medicine. https://doi.org/10.1002/sim.70733

Vancouver

Kojima M, Yamada K, Sunami H, Takeda K, Hanada K. Hybrid Non‐Informative and Informative Prior Model‐Assisted Designs for Mid‐Trial Dose Insertion. Statistics in Medicine. 2026. doi:10.1002/sim.70733

BibTeX
@article{Kojima2026,
  author = {Kojima, Masahiro and Yamada, Kana and Sunami, Hisato and Takeda, Kentaro and Hanada, Keisuke},
  title = {Hybrid Non‐Informative and Informative Prior Model‐Assisted Designs for Mid‐Trial Dose Insertion},
  journal = {Statistics in Medicine},
  year = {2026},
  doi = {10.1002/sim.70733}
}
Kostenlos starten →